Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia

International Journal of Clinical Pharmacology and Therapeutics

Volumn 39, Issue 12, 2001, Pages 551-557

  Okopien, B ^a   Cwallina, L ^a   Lebek, M ^a   Kowalski, J ^a   Zielinski, M ^a   Wisniewska Wanat, M ^a   Kalina, Z ^a   Herman, Z S ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Fibrates; Fibrinogen; PAl 1; Type IIb dyslipidemia

Indexed keywords

ATORVASTATIN; CIPROFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FIBRINOGEN; LIPID; PLASMINOGEN ACTIVATOR INHIBITOR; PROTHROMBIN;

ADULT; ARTICLE; ATHEROGENESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLICATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; DRUG EFFECT; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOGEN SYNTHESIS; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MALE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

EID: 0035204047     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP39551     Document Type: Article

References (23)

1. 2+ concentration in hemodialysed patients with secondary hyperparathyreoidism
2. How do we have to use the calcium in the dialysate to optimize the management of secondary hyperparathyroidism
3. Calcium kinetics and long-term effects of lowering dialysate calcium concentration
4. Sequenztherapie mittels intermittierender intravenöser und oraler Gabe von Alfacalcidol bei sekundärem renalem Hyperparathyreoidismus
5. Long term effects on intravenous 1-alpha(OH)D combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis
6. Long term effects of intermittent oral alfacalcidol, calcium carbonate and low-calcium dialysis (1,25 mmol/l) on secondary hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis
7. Calcium balance during pulse alfacalcidol therapy for secondary hyper-parathyroidism in CAPD patients treated with 1.0 and 1.25 mmol/l dialysate calcium
8. Calcium-Phosphat-Haushalt im frühen Stadium renaler Osteodystrophie
9. Impact of low calcium dialysate on the bone metabolism
10. 3 derivates in the treatment of renal bone disease: Justification and optimal modalities of administration
11. Vergleich der klinischen Wirksamkeit von Alfacalcidol und Calcitriol hinsichtlich ihrer Suppression des renalen sekundären Hyperparathyreoidismus
12. Beeinflußung des renalen sekundären Hyperparathyreoidismus durch 1-alpha-hydroxilierte Vitamin-D-Metaboliten
13. Aktive Vitamin-D-Metaboliten zur Behandlung des sekundären Hyperparathyreoidismus
14. Renal osteodystrophy
15. The use of alfacalcidol in the prevention of bone disease in early renal failure
16. 3 in patients on chronic hemodialysis
17. Effect of intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients
18. Control of serum-phosphate in patients with renal failure - New approaches
19. What is the appropriate calcium concentration for the dialysis patient?
20. Optimum route of administration of vitamin D in renal failure
21. 3 in hemodialysis in patients with moderate to severe secondary hyperparathyreoidism
22. Effect of treatment with 1,25 and 1,75 mmol/l calcium dialysate on bone mineral density in hemodialysis patients